Celldex Therapeutics, Inc. Stock Analysis & AI Score
Celldex Therapeutics, Inc. (CLDX) has an ST Score of 49.8 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $66.80 price target (+112.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Celldex Therapeutics, Inc. (CLDX) has an ST Score of 49.8 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). Analysts rate it Buy with a $66.80 price target (+112.2% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthF
All factor grades
- Financial StrengthA+
- ForecastA
- MomentumB
- ProfitabilityC+
- SentimentC+
- ValuationC
- GrowthF
- Piotroski2/9
Contact
CLDX stock: frequently asked questions
What is CLDX's ST Score?
Celldex Therapeutics, Inc. (CLDX) has an ST Score of 49.8 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CLDX a buy, hold, or sell?
Analysts rate CLDX a Buy, with a price target of $66.80 (+112.2% vs the current price). Our ST Score grades it C+ (49.8/100). The ST Score is a data-driven signal, not a recommendation.
What are CLDX's factor grades?
Valuation C, Profitability C+, Financial Strength A+, Momentum B, Growth F, Forecast A, Sentiment C+.
What is CLDX's valuation grade?
Celldex Therapeutics, Inc. (CLDX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CLDX's growth grade?
Celldex Therapeutics, Inc. (CLDX) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CLDX's profitability grade?
Celldex Therapeutics, Inc. (CLDX) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CLDX's financial strength grade?
Celldex Therapeutics, Inc. (CLDX) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CLDX?
The average analyst price target for Celldex Therapeutics, Inc. (CLDX) is $66.80 from 20 analysts, which is +112.2% versus the recent price of $31.48.
What is CLDX's Piotroski score?
Celldex Therapeutics, Inc. (CLDX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.